The same product would be the clearest path, to be sure. But I'm curious to know how this will impact the OTC product, particularly as it gets closer to FDA approval. What are the implications of selling the same product in prescription form and in retail stores? How would this complicate partnerships?
Lots of questions to answer, as this entire arrangement is screwy. Also, what else is Roskamp getting out of this collaborative/merged research? Who will be paying them as they get more involved? I'm seeing blurred lines and a long future of dilution.
There is also the potential of a spiteful FDA, 'paying back' Star for past transgressions (anatabloc health claims, etc.) as they enter new phases of drug development, beginning with the IND.
How will study results be announced? If positive, wouldn't that equate to making health claims on an OTC supplement? What about the previous research? If the IND is approved, will they then be able to repost those studies? Will they have to avoid making a direct reference to the currently marketed Anatabloc?
The above, of course, is the bull case. There is always the possibility that anatabine won't replicate earlier results with more rigorous future studies, whether it be due to design/technical issues, or the lack of punch that anatabine shows.
